🔴 Moderna is trading 11.2% down in pre-market after apparent profit-taking following August 19's 176.97% surge

Moderna is trading 11.2% down at $154.91 after investors appeared to take profits following its 176.97% regular-session surge on August 19.

• The rally followed positive Phase 3 INTerpath-001 results for intismeran autogene with Merck’s KEYTRUDA, improving recurrence-free and distant metastasis-free survival in resected melanoma patients.
• No new negative company announcement was identified overnight; the pre-market decline appears to reflect post-rally consolidation.